Cargando…
Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer
PURPOSE OF REVIEW: For decades, early-stage resectable non-small cell lung cancer (NSCLC), while potentially curable, has been marred by unacceptably high recurrence rates. RECENT FINDINGS: Anti-PD(L)1 immune checkpoint blockade (ICB) has revolutionized the treatment of advanced NSCLC, and with rece...
Autores principales: | Parekh, Jay, Parikh, Kaushal, Reuss, Joshua E., Friedlaender, Alex, Addeo, Alfredo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326100/ https://www.ncbi.nlm.nih.gov/pubmed/37249833 http://dx.doi.org/10.1007/s11912-023-01430-4 |
Ejemplares similares
-
Neoadjuvant Immunotherapy: A Promising New Standard of Care
por: Boydell, Emma, et al.
Publicado: (2023) -
Identifying successful biomarkers for patients with non-small-cell lung cancer
por: Friedlaender, Alex, et al.
Publicado: (2019) -
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung
Cancer
por: Baudoux, Nathalie, et al.
Publicado: (2023) -
Drugging KRAS: current perspectives and state-of-art review
por: Parikh, Kaushal, et al.
Publicado: (2022) -
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
por: Friedlaender, Alex, et al.
Publicado: (2020)